Biotechnology & Life Sciences Global On demand · 24-48h

Global Blood & Tissue DNA Kit Market Strategic Research Report

Global Blood & Tissue DNA Kit Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Blood & Tissue DNA Kit Market
$3072025
6.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Whole Blood, Plasma or Serum, Buffy Coat

By Application: R&D Organisations, Biotechnology Companies

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: QIAGEN, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Roche, Axygen (Corning), Analytik Jena, Promega, Zymo Research, Illumina, Macherey-Nagel, Bio-Rad, Omega Bio-tek, Geneaid, Lucigen (Biosearch Technologies), Norgen, MGI Tech Co., Ltd., BioVision

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 145 pages
Market size 2025
$307
Million USD
Forecast CAGR
6.6%
2025-2032
Forecast 2032
$480.2
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Blood & Tissue DNA Kit market size is predicted to grow from US$ 307 million in 2025 to US$ 484 million in 2032; it is expected to grow at a CAGR of 6.6% from 2026 to 2032.

In 2025, global Blood & Tissue DNA Kits approximately 3697 k units, with an average global market price of around US$ 85 per unit. Gross margin is about 48%. The cost is 44 usd. The Production is about 4200 k units. Blood & Tissue DNA Kit is a sample preparation reagent system used to isolate and purify high-quality genomic DNA from blood and tissue specimens through cell lysis, protein digestion, and DNA binding and elution processes. Upstream, it relies on lysis buffers, enzymes, spin columns or magnetic beads, and consumable plastics. Downstream, it serves as a fundamental input for PCR, qPCR, NGS library preparation, genotyping, and molecular diagnostics, and is widely used by clinical laboratories, research institutes, biotech companies, and diagnostic kit manufacturers as a core tool in molecular biology workflows.

Global key Blood & Tissue DNA Kit players cover QIAGEN, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Roche, Axygen (Corning), etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Blood & Tissue DNA Kit market?

What factors are driving Blood & Tissue DNA Kit market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Blood & Tissue DNA Kit market opportunities vary by end market size?

How does Blood & Tissue DNA Kit break out by Type, by Application?

This report presents a comprehensive overview of the global Blood & Tissue DNA Kit market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Whole Blood
  • Plasma or Serum
  • Buffy Coat

Segment by Technology

  • Spin Column-based DNA Kit
  • Magnetic Bead-based DNA Kit
  • Precipitation-based DNA Kit

Segment by Application

  • R&D Organisations
  • Biotechnology Companies

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Blood & Tissue DNA Kit market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in R&D Organisations, Biotechnology Companies evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Blood & Tissue DNA Kit Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$307
2025
Forecast
$480.2
2032
CAGR
6.6%
2025–2032
Regionen
5
global
Key companies
QIAGENThermo Fisher ScientificSigma-Aldrich (Merck)RocheAxygen (Corning)Analytik JenaPromegaZymo Research
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Whole BloodPlasma or SerumBuffy Coat
By Application
R&D OrganisationsBiotechnology Companies

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Whole Blood
  • 3.1.3 Plasma or Serum
  • 3.1.4 Buffy Coat
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 R&D Organisations
  • 4.1.3 Biotechnology Companies
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 QIAGEN
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Thermo Fisher Scientific
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Sigma-Aldrich (Merck)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Roche
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Axygen (Corning)
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Analytik Jena
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Promega
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Zymo Research
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Illumina
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Macherey-Nagel
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Bio-Rad
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Omega Bio-tek
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Geneaid
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Lucigen (Biosearch Technologies)
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Norgen
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 MGI Tech Co., Ltd.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 BioVision
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Blood & Tissue DNA Kit market?
The global Blood & Tissue DNA Kit market is estimated at US$ 307 million in 2025 (base year) and is projected to reach US$ 484 million by 2032.
How fast is the Blood & Tissue DNA Kit market expected to grow?
The market is expected to grow at a CAGR of 6.6% from 2026 to 2032, expanding from US$ 307 million in 2025 to US$ 484 million in 2032, roughly 1.6 times its base-year value.
What does the Blood & Tissue DNA Kit market cover?
In 2025, global Blood & Tissue DNA Kits approximately 3697 k units, with an average global market price of around US$ 85 per unit. Gross margin is about 48%. The cost is 44 usd.
What are the main segments of the Blood & Tissue DNA Kit market by type?
By type, the market is segmented into Whole Blood, Plasma or Serum and Buffy Coat.
Which applications drive demand in the Blood & Tissue DNA Kit market?
Key applications covered include R&D Organisations and Biotechnology Companies.
Who are the key players in the Blood & Tissue DNA Kit market?
Key players profiled include QIAGEN, Thermo Fisher Scientific, Sigma-Aldrich (Merck), Roche, Axygen (Corning), Analytik Jena, Promega and Zymo Research, among 17 companies covered in total.
Which regions and countries are covered for Blood & Tissue DNA Kit?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Blood & Tissue DNA Kit market?
What factors are driving Blood & Tissue DNA Kit market growth, globally and by region?
Who should buy the Blood & Tissue DNA Kit market report?
The report is intended for manufacturers and solution providers, distributors and end users in R&D Organisations and Biotechnology Companies, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Blood & Tissue DNA Kit market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.